mRNA Vaccine Protects Lactating Dairy Cows Against H5N1 Influenza
Novel mRNA-LNP vaccine significantly reduces viral shedding and mastitis in infected dairy cattle.
1H5N1 Impact on Dairy
The HPAI clade 2.3.4.4b H5N1 virus has emerged in US dairy cattle, causing severe mastitis and sharp declines in milk production. Unlike respiratory-focused influenza, this virus primarily replicates in mammary tissue. Transmission occurs through viral shedding in milk, creating significant economic losses and raising concerns about potential mammalian adaptation and human health risks.
2Vaccine Development Strategy
Researchers developed an mRNA-lipid nanoparticle vaccine encoding the hemagglutinin of the A/dairy cattle/Texas/24-008749-002/2024 virus. This vaccine was designed to target circulating bovine strains. The study assessed immunogenicity and efficacy in eight lactating cows, comparing a vaccinated group receiving two intramuscular doses against a control group administered saline before an intramammary viral challenge.
3Robust Immune Response
Vaccination successfully elicited HA-reactive and neutralizing antibodies in both serum and milk. Results showed that neutralizing antibodies were detectable 21 days after the initial dose and increased significantly following the booster. All four vaccinated animals demonstrated consistent antibody production, effectively blocking viral attachment to erythrocytes in hemagglutination inhibition assays conducted before the challenge.
4Viral Shedding Reduction
Following the intramammary viral challenge, vaccinated cows exhibited approximately 1,000-fold lower peak viral RNA levels in their milk compared to the control group. This reduction in viral load correlates with a lower incidence of clinical mastitis and mammary fibrosis, suggesting the vaccine provides substantial protection against the primary symptoms of the H5N1 infection.
5Safety and mRNA Detection
The vaccine was well tolerated with no observed adverse effects in the study subjects. Researchers utilized a sensitive quantitative PCR assay with a detection limit of 65 mRNA copies per microliter to monitor milk. No vaccine-derived mRNA was detected in milk samples collected up to eight days after either the prime or boost vaccination.
6Preexisting Antibody Analysis
Two cows showed low levels of H5-reactive IgG before the study, though they tested negative for H5N1. Researchers hypothesize these were cross-reactive antibodies from previous human influenza A virus exposure, supported by detectable H1-reactive antibodies. Despite this, the vaccinated animal in this subgroup produced robust H5-specific responses comparable to the other vaccinated cows.
7Targeting HA Epitopes
Pseudovirus deep mutational scanning identified that neutralizing antibodies primarily target antigenic sites A and B on the globular head of the hemagglutinin protein. These specific sites are adjacent to the receptor-binding domain. Crucially, these targeted amino acid identities are highly conserved across circulating clade 2.3.4.4b viruses, suggesting the vaccine remains effective against current strains.
8Milk Antibody Dynamics
While H5-reactive IgG was detected in milk, peak levels were lower than those observed in serum. Furthermore, antibody concentrations in milk declined more rapidly than in the bloodstream. Due to the presence of nonspecific inhibitors in bovine milk, researchers were unable to perform in vitro neutralization assays directly on the milk samples collected.
9Experimental Methodology
The study utilized Holstein cows aged 2 to 8 years from an HPAI-monitored herd in Pennsylvania. The prime-boost regimen involved a 500-microgram dose administered intramuscularly, with a booster three weeks later. Viral challenge occurred 49 days after the first vaccination, allowing for a comprehensive assessment of the vaccine's protective efficacy against the specific bovine strain.
10Comparative Vaccine Context
Previous research on bovine vaccines, such as the Mycobacterium bovis-BoHV-1 combined vaccine, has demonstrated the feasibility of eliciting antigen-specific maternal antibodies. While other H5N1 vaccines have been tested in bovine models, this study specifically addresses the need for systematic evaluation of immunogenicity and protective efficacy against intramammary infection in lactating dairy cows.
11Broader Public Health Implications
The H5N1 outbreak in cattle represents a significant concern for human health due to the risk of mammalian adaptation and potential human-to-human transmission. By limiting viral replication and shedding in dairy cattle, this mRNA-LNP vaccine could serve as a critical tool for controlling the outbreak and reducing the risk of spillover events into humans.
12Future Vaccination Outlook
This study provides evidence that an mRNA-LNP vaccine can effectively protect lactating dairy cows from H5N1 infection. By reducing mastitis and viral shedding, such vaccination strategies could mitigate economic losses in the dairy industry. Future efforts should focus on scaling production and evaluating long-term immunity to ensure sustained protection against evolving avian influenza strains.